Total Payments
$836,905
2024 Payments
$29,640
Companies
61
Transactions
1,887
Medicare Patients
7,837
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$702,261 (83.9%)
Travel$85,450 (10.2%)
Food & Beverage$33,088 (4.0%)
Consulting$15,981 (1.9%)
Education$125.55 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $664,772 | 294 | 79.4% |
| Travel and Lodging | $85,450 | 356 | 10.2% |
| Honoraria | $37,489 | 27 | 4.5% |
| Food and Beverage | $33,088 | 1,197 | 4.0% |
| Consulting Fee | $15,981 | 8 | 1.9% |
| Education | $125.55 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $436,486 | 466 | $0 (2024) |
| Chiesi USA, Inc. | $183,282 | 281 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $101,704 | 179 | $0 (2022) |
| ABBVIE INC. | $50,194 | 188 | $0 (2024) |
| Biogen, Inc. | $33,109 | 21 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $19,009 | 40 | $0 (2024) |
| Allergan, Inc. | $1,389 | 59 | $0 (2022) |
| UCB, Inc. | $987.30 | 42 | $0 (2024) |
| SK Life Science, Inc. | $851.63 | 40 | $0 (2024) |
| Amgen Inc. | $840.99 | 44 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,640 | 147 | Janssen Pharmaceuticals, Inc ($12,373) |
| 2023 | $45,255 | 211 | AbbVie Inc. ($17,395) |
| 2022 | $105,200 | 265 | Janssen Pharmaceuticals, Inc ($80,919) |
| 2021 | $131,537 | 342 | Avanir Pharmaceuticals, Inc. ($55,511) |
| 2020 | $53,899 | 201 | Janssen Pharmaceuticals, Inc ($29,675) |
| 2019 | $123,163 | 222 | Janssen Pharmaceuticals, Inc ($58,108) |
| 2018 | $183,812 | 277 | Janssen Pharmaceuticals, Inc ($111,088) |
| 2017 | $164,400 | 222 | Janssen Pharmaceuticals, Inc ($112,560) |
All Payment Transactions
1,887 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Travel and Lodging | Cash or cash equivalent | $607.28 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/19/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $3.62 | General |
| Category: PAIN | ||||||
| 11/12/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Neuroscience | ||||||
| 11/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: PAIN | ||||||
| 11/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.78 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Respiratory | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.27 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Food and Beverage | Cash or cash equivalent | $124.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $3.78 | General |
| Category: PAIN | ||||||
| 10/08/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: UROLOGY | ||||||
| 10/08/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: NEUROSCIENCE | ||||||
| 10/01/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.53 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,994 | 3,853 | $726,248 | $330,562 |
| 2022 | 18 | 2,074 | 3,794 | $674,067 | $316,876 |
| 2021 | 17 | 2,167 | 4,160 | $751,782 | $366,020 |
| 2020 | 19 | 1,602 | 3,214 | $516,122 | $239,737 |
Total Patients
7,837
Total Services
15,021
Medicare Billing
$1.3M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 203 | 910 | $345,330 | $148,019 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 250 | 381 | $60,990 | $33,111 | 54.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 175 | 197 | $53,570 | $24,954 | 46.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 180 | 374 | $46,675 | $22,811 | 48.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 173 | 353 | $45,890 | $21,371 | 46.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 270 | 294 | $44,100 | $18,585 | 42.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 130 | 130 | $23,400 | $16,072 | 68.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 174 | 382 | $28,650 | $14,478 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 74 | 76 | $23,940 | $10,090 | 42.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 142 | 155 | $22,475 | $9,571 | 42.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 56 | 62 | $13,950 | $6,167 | 44.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 24 | 49 | $5,880 | $2,212 | 37.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $4,250 | $1,943 | 45.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 71 | 75 | $1,725 | $467.25 | 27.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 49 | $1,715 | $377.30 | 22.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 30 | 337 | $3,360 | $235.51 | 7.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 12 | 12 | $348.00 | $98.91 | 28.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 183 | 736 | $276,000 | $123,970 | 44.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 219 | 335 | $53,688 | $30,664 | 57.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 334 | 351 | $52,650 | $27,030 | 51.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 165 | 189 | $51,030 | $25,060 | 49.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 181 | 426 | $54,304 | $23,370 | 43.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 141 | 295 | $36,825 | $17,932 | 48.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 114 | 117 | $36,855 | $17,903 | 48.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 195 | 472 | $34,785 | $14,067 | 40.4% |
About Dr. Scott Brehaut, MD
Dr. Scott Brehaut, MD is a Family Medicine healthcare provider based in Clinton, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245253541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Brehaut, MD has received a total of $836,905 in payments from pharmaceutical and medical device companies, with $29,640 received in 2024. These payments were reported across 1,887 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($664,772).
As a Medicare-enrolled provider, Brehaut has provided services to 7,837 Medicare beneficiaries, totaling 15,021 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Clinton, NY
- Active Since 07/26/2006
- Last Updated 06/25/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245253541
Products in Payments
- XARELTO (Drug) $436,359
- CLEVIPREX (Drug) $181,427
- NUEDEXTA (Drug) $101,748
- QULIPTA (Drug) $26,513
- UBRELVY (Drug) $24,209
- SAMSCA (Drug) $16,319
- TOLVAPTAN (Drug) $2,611
- CLEVIPREX 25MG/50ML (Drug) $1,552
- Briviact (Drug) $955.97
- NURTEC ODT (Drug) $673.96
- XIFAXAN (Drug) $572.93
- ENTRESTO (Drug) $479.70
- VRAYLAR (Drug) $402.27
- EMGALITY (Drug) $394.22
- Aimovig (Biological) $392.47
- TROKENDI XR (Drug) $355.42
- INGREZZA (Drug) $319.52
- AUSTEDO (Drug) $283.68
- Otezla (Drug) $265.34
- FARXIGA (Drug) $254.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Clinton
Dr. Tyler Dixon, D.o, D.O
Family Medicine — Payments: $37,323
Family Medicine $37,323
Neal Goodbar, Md, MD
Family Medicine — Payments: $13,086
Family Medicine $13,086
Dr. Arturo Blanco, Md, MD
Family Medicine — Payments: $12,392
Family Medicine $12,392
Dr. Scott Martin, M.d, M.D
Family Medicine — Payments: $12,150
Family Medicine $12,150
Melody Tharp, Md, MD
Family Medicine — Payments: $11,425
Family Medicine $11,425
Eric Hogan, D.o, D.O
Family Medicine — Payments: $7,997
Family Medicine $7,997